Levosalbutamol in the treatment of asthma

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 12, 2006, Pages 1659-1668

  Milgrom, Henry ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

2 agonists; (S) salbutamol; Asthma; Levosalbutamol

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ; CORTICOSTEROID; DEXAMETHASONE; FORMOTEROL; HISTAMINE; IPRATROPIUM BROMIDE; LEUKOTRIENE C4; LEVALBUTEROL; PLACEBO; SALBUTAMOL;

AIRWAY RESISTANCE; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CLINICAL FEATURE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FLUID; LUNG FUNCTION TEST; LUNG LYMPH FLOW; METERED DOSE INHALER; NEBULIZATION; NONHUMAN; RACEMIC MIXTURE; RACEMIZATION; RISK ASSESSMENT; SPIROMETRY; STEREOISOMERISM; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ALBUTEROL; ANIMALS; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY FUNCTION TESTS; STEREOISOMERISM;

EID: 33747044684     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.12.1659     Document Type: Article

References (43)

1. WIELAND K, ZUURMOND HM, KRASEL C, IJZERMAN AP, LOHSE MJ: Involvement of Asn-293 in stereospecific agonist recognition and in activation of the β2-adrenergic receptor. Proc. Natl. Acad. Sci. USA (1996) 93:9276-9281.
2. PENN RB, FRIELLE T, MCCULLOUGH JR, ABERG G, BENOVIC JL: Comparison of R-, S-, and RS-albuterol interaction with human β1- and β2-adrenergic receptors. Clin. Rev. Allergy Immunol (1996) 14:37-45.
3. COCKCROFT DW, SWYSTUN VA: Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax (1997) 52:845-848.
4. IND PW: Salbutamol enantiomers: early clinical evidence in humans. Thorax (1997) 52:839-840.
5. 2+ signalling and contraction of airway smooth muscle by cyclic AMP-dependent mechanisms. Br. J. Pharmacol. (1996) 117:419-426.
6. MITRA S, UGUR M, UGUR O, GOODMAN HM, MCCULLOUGH JR, YAMAGUCHI H: (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol. Pharmacol. (1998) 53:347-354.
7. AGRAWAL DK, ARIYARATHNA K, KELBE PW: (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J. Allergy Clin. Immunol. (2004) 113:503-510.
8. VOLCHECK G, GLEICH G, KITA H: Pro- and anti-inflammatory effects of β-adrenergic agonists on eosinophil response to IL-5. J. Allergy Clin. Immunol. (1998) 101:S35.
9. CHO SH, HARTLEROAD JY, OH CK: (S)-Albuterol increases the production of histamine and IL-4 in mast cells. Int. Arch. Allergy Immunol (2001) 124:478-484.
10. BARAMKI D, KOESTER J, ANDERSON AJ, BORISH L: Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J. Allergy Clin. Immunol. (2002) 109:449-454.
11. SAUNDERS MA, MITCHELL JA, SELDON PM et al.: Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br. J. Pharmacol. (1997) 120:545-546.
12. ENDO T, UCHIDAY, NOMURA A et al.: Activated eosinophils stimulate endothelin-1 release from airway epithelial cells by direct adherence via adhesion molecules. Pulm. Pharmacol. Ther. (1997) 10:81-87.
13. HALLSWORTH MP, SOH CP, TWORT CH, LEE TH, HIRST SJ: Cultured human airway smooth muscle cells stimulated by interleukin-1β enhance eosinophil survival. Am. J. Respir. Cell Mol. Biol. (1998) 19:910-919.
14. AMEREDES B, CALHOUN W: Modulation of GM-CSF release by enantiomers of β2-agonists in human airway smooth muscle. J. Allergy Clin. Immunol. (2005) 116:65-72.
15. GIBSON B, FRIDAY S, WATKINS S, AMEREDES B, CALHOUN W: Effects of dexamethasone and β-agonist enantiomers on glucocorticoid receptor translocaton. J. Allergy Clin. Immunol. (2005) 115:S59.
16. KEIR S, PAGE C, SPINA D: Bronchial hyperresponsiveness induced by chronic treatment with albuterol: role of sensory nerves. J. Allergy Clin. Immunol. (2002) 110:388-394.
17. AGRAWAL D, CLARK K, TOWNLEY R: Dfferential effects of albuterol enantiomers on pulmonary functions and bronchoalveolar lavage (BAL) eosinophilia. Am. J. Respir. Crit. Care Med. (2000) 161:A191.
18. PETERSON B, MILLER E: Effects of enantiomers of albuterol on lung epithelial permeability. Am. J. Respir. Crit. Care Med. (2000) 161:A416.
19. RAMSAY CM, COWAN J, FLANNERY E, MCLACHLAN C, TAYLOR DR: Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur. J. Clin. Pharmacol. (1999) 55:353-359.
20. NELSON HS, BENSCH G, PLESKOW WW et al.: Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J. Allergy Clin. Immunol. (1998) 102:943-952.
21. PLESKOW WW, NELSON HS, SCHAEFER K, CLAUS R, ROACH JM: Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc. (2004) 25:429-436.
22. LOTVALL J, PALMQVIST M, ARVIDSSON P, MALONEY A, VENTRESCA GP, WARD J: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J. Allergy Clin. Immunol. (2001) 108:726-731.
23. MILGROM H, SKONER D, BENSCH G, KIM K, CLAUS R, BAUMGARTNER R: Reply. J. Allergy Clin. Immunol. (2002) 110:325-328.
24. DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION: In: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994). (Available at http://www.ich.org/cache/compo/475-272-1.html).
25. NOWAK R, EMERMAN C, CLAUS R et al.: Levalbuterol (LEV) versus racemic albuterol (RAC) in acute severe asthma: a prospective trial. Am. J. Emerg. Med. (2004) 22(1):29-36.
26. NOWAK R, EMERMAN C, HANRAHAN JP et al.: A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am. J. Emerg. Med. (2006) 24:259-267.
27. TRUITT T, WITKO J, HALPERN M: Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest (2003) 123:128-135.
28. HAIDER D: Levalbuterol affords superior health and cost benefit over racemic albuterol in the emergency department. Respir. Care (2001) 46:1081.
29. GAWCHIK SM, SACCAR CL, NOONAN M, REASNER DS, DEGRAW SS: The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J. Allergy Clin. Immunol. (1999) 103:615-621.
30. MILGROM H, SKONER DP, BENSCH G, KIM KT, CLAUS R, BAUMGARTNER RA: Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J. Allergy Clin. Immunol. (2001) 108:938-945.
31. CARL JC, MYERS TR, KIRCHNER HL, KERCSMAR CM: Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J. Pediatr. (2003) 143:731-736.
32. SKONER DP, GREOS LS, KIM KT, ROACH JM, PARSEY M, BAUMGARTNER RA: Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr. Pulmonol. (2005) 40:477-486.
33. HARTMAN AP, WILSON AA, WILSON HM, ABERG G, FALANY CN, WALLE T: Enantioselective sulfation of β2-receptor agonists by the human intestine and the recombinant M-form phenolsulfotransferase. Chirality (1998) 10:800-803.
34. WARD JK, DOW J, DALLOW N, EYNOTT P, MILLERI S, VENTRESCA GP: Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man-no evidence of enantioselective lung metabolism. Br. J. Clin. Pharmacol. (2000) 49:15-22.
35. MAIER G, RUBINO C, HSU R, GRASELA T, BAUMGARTNER R: Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4 to 11 years with asthma. (2005).
36. SCHMEKEL B, RYDBERG I, NORLANDER B, SJOSWARD KN, AHLNER J, ANDERSSON RG: Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur. Respir. J. (1999) 13:1230-1235.
37. DHAND R, GOODE M, REID R, FINK JB, FAHEY PJ, TOBIN MJ: Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am. J. Respir. Crit. Care Med. (1999) 160:1136-1141.
38. THOMPSON M, WISE S, RODENBERG H: A preliminary comparison of levalbuterol and albuterol in prehospital care. J. Emerg. Med. (2004) 26:271-277.
39. HARDASMALANI MD, DEBARI V, BITHONEY WG, GOLD N: Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr. Emerg. Care (2005) 21:415-419.
40. QURESHI F, ZARITSKY A, WELCH C, MEADOWS T, BURKE BL: Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann. Emerg. Med. (2005) 46:29-36.
41. RALSTON ME, EUWEMA MS, KNECHT KR, ZIOLKOWSKI TJ, COAKLEY TA, CLINE SM: Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J. Emerg. Med. (2005) 29:29-35.
42. BERGER WE, AMES DE, HARRISON D: A patient satisfaction survey comparing levalbuterol with racemic albuterol in children. Allergy Asthma Proc. (2004) 25:437-444.
43. BERGER WE: Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann. Allergy Asthma Immunol (2003) 90:583-591.